What Biovet does

Biovet Private Ltd. is an Indian animal health vaccine manufacturer headquartered at the KIADB Industrial Area in Malur, Kolar District, Karnataka, approximately 40 kilometers from Bangalore. The company produces veterinary biologicals and bio-vaccines for large animals, poultry, and pet animals, with a core focus on Foot and Mouth Disease (FMD) and other economically significant livestock diseases including Bluetongue, Haemorrhagic Septicaemia, Johne's Disease, Black Quarter, and Enterotoxemia. Its vaccines are sold under the BioFMD, BioBT, BioHS, BioHSBQ, BioJD, BioBQ, and BioET brands in both oil-emulsion and gel formulations designed to deliver stable, long-lasting immunity at low dosage volumes (1-2 mL per animal).

The company's central technical differentiator is its BSL-3 + Ag (Biosafety Level 3 + Agriculture) production facility — India's first and the world's second such facility — constructed 5 meters below soil level with in-built effluent treatment and kill tank infrastructure. The facility was built with an INR 150 crore investment, funded by the Technology Development Board (TDB) of the Government of India, with R&D supported by NMTLI grants. Vaccine technology was originally transferred from premier Indian institutions including TANUVAS, IVRI, PDFMD (ICAR), and CIRG (ICAR), and the company now maintains an in-house research team of more than 100 researchers supported by an Antigen Bank system. The company received the National Technology Award from the President of India in 2013.

Biovet operates a sales-led, direct distribution model targeting rural livestock farmers in India through a public-private partnership framework originally designed to deliver quality vaccines at the grassroots level. Revenue is generated through one-time sale of vaccines and animal health products rather than subscription or licensing arrangements; no pricing is publicly disclosed. In 2019 the company announced plans to invest Rs 200 crore in expanding its Malur facility to add Brucellosis vaccine capacity, and in 2026 it disclosed its first international commercial channel — a partnership with Brazil's Petlove to distribute veterinary medications in the R$ 3.2 billion Brazilian veterinary medications segment.

Name

Biovet

Legal name

Biovet Private Ltd.

Website

https://biovet.in

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Biovet Private Ltd. is an Indian animal health vaccine manufacturer operating India's first BSL-3+Ag production facility in Malur, Karnataka, producing FMD, Bluetongue, and other livestock vaccines for rural farmers, poultry operators, and pet owners across India and select international markets.

Ownership category

akta.pro rank

Product category

Animal Health Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Veterinary Vaccines (HLAIAEAH)

Keywords

• Veterinary biologicals
• Animal vaccines
• Livestock health
• Foot and mouth disease
• BSL-3 vaccine production

Headquarters

HQ city

Kolar

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Vaccine and Animal Health Product Sales: Biovet generates revenue through the sale of veterinary biologicals, bio-vaccines, and animal health products including Foot and Mouth Disease vaccines, Bluetongue Disease vaccines, Haemorrhagic Septicaemia vaccines, Johne's Disease vaccines, Black Quarter Disease vaccines, and Enterotoxemia Disease vaccines for large animals, poultry, and pet animals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Biovet Private Ltd. manufactures and sells veterinary biologicals and bio-vaccines for large animals, poultry, and pet animals. Its portfolio covers inactivated Foot and Mouth Disease (BioFMD-Oil), Bluetongue Disease (BioBT-Oil/Gel), Haemorrhagic Septicaemia (BioHS-Oil/Gel), combined Haemorrhagic Septicaemia and Black Quarter (BioHSBQ-Oil/Gel), Johne's Disease (BioJD-Oil/Gel), Black Quarter (BioBQ-Gel), and Enterotoxemia (BioET-Gel) vaccines in oil emulsion and gel formulations. Vaccines are produced at India's first BSL-3 + Ag Production Facility in Malur, Karnataka.

Product overview

Biovet is an animal health vaccine company specializing in veterinary biologicals and bio-vaccines. The company operates a world-class manufacturing facility in Malur, Karnataka (near Bangalore), producing vaccines for large animals, poultry, and pet animals. The product portfolio includes disease-specific vaccines across multiple formulations: BioFMD-Oil (Foot and Mouth Disease), BioBT-Oil/Gel (Bluetongue Disease), BioHS-Oil/Gel (Haemorrhagic Septicaemia), BioHSBQ-Oil/Gel (combined Haemorrhagic Septicaemia and Black Quarter), BioJD-Oil/Gel (Johne's Disease), BioBQ-Gel (Black Quarter), and BioET-Gel (Enterotoxemia). Vaccines are available in both oil and gel formulations to suit different administration preferences and immunity duration requirements.

Differentiator

Problem solved

Functional benefit

Products and services

• BioFMD-Oil

Quantifiable outcome

• Provides livestock health solutions at farmers' doorstep, removing trade barriers during creation of economic zones
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• PetlovecoreChannel Partner/ Reseller/ Distributor · 18 June 2026Biovet is a partner pharmaceutical firm in Petlove's PetVet medication benefits program (PBM), offering up to 40% discounts on approximately 140 veterinary medications to address low treatment adherence among Brazil's 160 million pets. The partnership targets the R$ 3.2 billion veterinary medications segment projected to grow 9-11% annually until 2034.
• TANUVAS (Tamil Nadu Veterinary and Animal Sciences University)coreStrategic or Co-development PartnerTechnology transfer partner for vaccine development and production processes. TANUVAS is a premier veterinary and animal sciences university providing technical expertise for Biovet's vaccine manufacturing capabilities.
• IVRI (Indian Veterinary Research Institute)coreStrategic or Co-development PartnerTechnology transfer partner under ICAR (Indian Council of Agricultural Research) for vaccine development and research collaboration.
• PDFMD (Project Directorate of Foot and Mouth Disease, ICAR)coreStrategic or Co-development PartnerTechnology transfer partner for Foot and Mouth Disease vaccine technology under ICAR. PDFMD is the nodal institute for FMD research in India.
• CIRG (Central Institute for Research on Goats, ICAR)minorStrategic or Co-development PartnerTechnology transfer partner under ICAR for goat disease research and vaccine development.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Vetoquinol SA: Global independent animal health company producing veterinary vaccines and pharmaceuticals for livestock and companion animals — comparable product portfolio targeting similar veterinary channels.
• Ceva Santé Animale: Global veterinary pharmaceutical and vaccine company with significant poultry and livestock vaccine portfolio serving emerging markets — competes in adjacent livestock vaccine categories globally.
• MSD Animal Health (Merck): Global animal health division of Merck offering comprehensive livestock vaccine portfolio including FMD via Intervet operations — directly overlaps Biovet's livestock vaccine category with global scale.
• Virbac SA: Global animal health pharmaceutical company producing veterinary vaccines, biologicals and pharmaceuticals for livestock and companion animals — comparable product category targeting similar veterinary channels.
• Zoetis Inc. World's largest animal health company offering a comprehensive vaccine and therapeutics portfolio for livestock and companion animals including FMD franchise — broader incumbent competing with Biovet in the same disease categories globally.
• Boehringer Ingelheim Animal Health: Global animal health leader with significant FMD, bluetongue and livestock vaccine portfolio across emerging markets — competes broadly with Biovet's livestock vaccine franchise through multinational distribution.
• Elanco Animal Health: Global animal health company with livestock vaccine portfolio serving emerging markets — broader incumbent offering competing products in same disease categories.

Direct peers

• Indian Immunologicals Limited: Indian animal vaccine manufacturer producing FMD, rabies, brucellosis and other veterinary biologicals from Indian government-affiliated (NDDB) and private production facilities — directly comparable livestock vaccine portfolio and India-centric distribution model.
• Hester Biosciences: Ahmedabad-headquartered Indian animal health company manufacturing poultry vaccines, large animal vaccines and animal health products — directly comparable product category, target market (rural India), and vaccine R&D orientation.
• Brilliant Bio Pharma Private Limited: Indian animal health pharmaceutical and vaccine manufacturer producing veterinary biologicals for livestock — directly comparable Indian-focused manufacturer competing in same product categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biovet-pvt-ltd-bangalore-india.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biovet